Antibiotics (Basel, Switzerland) · 2026
Plasma and Intracellular Concentrations of Doxycycline and Azithromycin in Patients with Severe Scrub Typhus.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kundu Debasree, Sebastian Merylin, Ahmad Shadab, Khan Sohail, Dayanand Divya, Aruldhas Blessed Winston, Mathew Binu Susan, Gunasekaran Karthik, Newbigging Nalini, Abhilash Kundavaram P P, Zachariah Anand, Iyadurai Ramya, Hansdak Samuel George, Sathyendra Sowmya, Sudarsanam Thambu David, Manesh Abi, Peter John Victor, Salje Jeanne, Abraham Ooriapadickal C, Day Nicholas P J, Tarning Joel, Varghese George M
Аннотация
BACKGROUND/OBJECTIVES: Scrub typhus, a life-threatening infection caused by Orientia tsutsugamushi, is treated with doxycycline or azithromycin. In severe disease, combination therapy with azithromycin and doxycycline had better clinical outcomes than either drug alone. However, it is not clear what causes the improved efficacy. To understand the same, we examined the plasma concentrations, intracellular concentrations, and efficacy of doxycycline, azithromycin, and both drugs in combination in 51 patients with severe scrub typhus.
METHODS: A randomly selected subset of adult (>18 years) participants from the INTREST trial (Clinical Trials Registry-India, number CTRI/2018/08/015159), who had been randomized in a 1:1:1 ratio to receive doxycycline, azithromycin, or both drugs, respectively, were included in this study for comparative drug concentration analysis. Blood samples were collected on days 0, 1, 3, and 7 to monitor bacterial load using quantitative polymerase chain reaction (PCR). Five milliliters of sterile blood were collected 3-10 h after the final dose on day 7 for comparative drug concentration measured using high-resolution multiple reaction monitoring. Data were analyzed in GraphPad Prism v.10.0.3.
RESULTS: Fifty-one patients (males, 59%; median age, 52 years) were enrolled. Fifteen, seventeen, and nineteen patients received azithromycin, doxycycline, and both, respectively. Doxycycline achieved a median plasma concentration of 1112 (42.51-5697) ng/mL and was undetectable intracellularly. The intracellular concentration of azithromycin (1127 [16.78-19,250] ng/mL) surpassed its plasma concentration (227.1 [48.78-1022] ng/mL). On day 3, PCR negativity rates were 56.24%, 93.3%, and 94.7% in the doxycycline, azithromycin, and combination groups, respectively.
CONCLUSIONS: The high plasma concentrations of doxycycline and intracellular accumulation of azithromycin may contribute to improved clinical outcomes when used in combination.
METHODS: A randomly selected subset of adult (>18 years) participants from the INTREST trial (Clinical Trials Registry-India, number CTRI/2018/08/015159), who had been randomized in a 1:1:1 ratio to receive doxycycline, azithromycin, or both drugs, respectively, were included in this study for comparative drug concentration analysis. Blood samples were collected on days 0, 1, 3, and 7 to monitor bacterial load using quantitative polymerase chain reaction (PCR). Five milliliters of sterile blood were collected 3-10 h after the final dose on day 7 for comparative drug concentration measured using high-resolution multiple reaction monitoring. Data were analyzed in GraphPad Prism v.10.0.3.
RESULTS: Fifty-one patients (males, 59%; median age, 52 years) were enrolled. Fifteen, seventeen, and nineteen patients received azithromycin, doxycycline, and both, respectively. Doxycycline achieved a median plasma concentration of 1112 (42.51-5697) ng/mL and was undetectable intracellularly. The intracellular concentration of azithromycin (1127 [16.78-19,250] ng/mL) surpassed its plasma concentration (227.1 [48.78-1022] ng/mL). On day 3, PCR negativity rates were 56.24%, 93.3%, and 94.7% in the doxycycline, azithromycin, and combination groups, respectively.
CONCLUSIONS: The high plasma concentrations of doxycycline and intracellular accumulation of azithromycin may contribute to improved clinical outcomes when used in combination.